A Study to Investigate the Absorption, Metabolism and Excretion of Talampanel

A Phase 1 Open-label Mass Balance Study to Investigate the Absorption, Metabolism and Excretion of [14C]-Talampanel Following Oral Administration to Healthy Male

The purpose of this study is to characterize the chemical breakdown and excretion of talampanel and its break down products in plasma, feces, and urine of healthy human volunteers.

Study Overview

• Status: Terminated
• Conditions: Healthy
• Intervention / Treatment: Drug: Talampanel (non-radiolabeled), [14C] Talampanel

• Study Type: Interventional
• Enrollment (Anticipated): 10
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • Wisconsin
    • Madison, Wisconsin, United States, 53704
      • Covance Clinical Pharmacology Inc.

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 55 years (Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: Male

Description

Inclusion Criteria:

• Males, between 18 and 55 years of age, inclusive
• Body Mass Index range 18.0 to 30.0 kg/m2, inclusive
• Have NAT2 slow or rapid acetylator genotype
• In good health as determined by the investigator
• Negative test for selected drugs of abuse at screening
• Negative screens for Hepatitis B, Hepatitis C and HIV
• Sterile or agrees to use an approved method of contraception from Check-in until 45 days following Clinic Discharge
• Able to comprehend and willing to sign an Informed Consent Form
• Have 1 to 2 bowel movements per day

Exclusion Criteria:

• Significant history or clinical manifestation of any significant metabolic, allergic, skin, liver, kidney, blood, heart or blood vessel, digestive system, brain or psychiatric disorder
• History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance
• History of stomach or intestinal surgery or resection
• History or presence of an abnormal ECG,
• History of clinically significant alcohol or drug use within 1 year prior to Check-in
• Participation in more than 1 other radiolabeled investigational study drug trial within 12 months prior to Check-in
• Exposure to significant radiation within 12 months prior to Check-in -Use of any tobacco- or nicotine-containing within 6 months prior to Check- in
• Use of any drugs which may interact with the study drug within 30 days prior to Check-in
• Participation in any other investigational study drug trial in which receipt of an investigational study drug occurred within 30 days prior to Check-in
• Use of any prescription medications/products within 14 days prior to Check in
• Use of any over-the-counter, non-prescription drugs within 7 days prior to Check-in
• Use of grapefruit or grapefruit-containing foods or beverages within 7 days prior to Check-in
• Use of alcohol- or caffeine-containing foods or beverages within 72 hours prior to Check-in
• Donation of blood from 30 days prior to Screening through Study Completion, inclusive, or of plasma from 2 weeks prior to Screening through Study Completion
• Receipt of blood products within 2 months prior to Check-in
• Any acute or chronic condition that would limit the subject's ability to complete and/or participate in this clinical study

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Slow and rapid N-acetyl transferase genotypes	Drug: Talampanel (non-radiolabeled), [14C] Talampanel; 50 mg capsule single dose; Other Names: TV-7600

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
To determine the mass balance of [14C]-talampanel. To characterize the metabolism of [14C] talampanel in plasma, feces, and urine. To assess the pharmacokinetics (PK) of total radioactivity, talampanel, and N-acetyl talampanel.	6-9 days

Secondary Outcome Measures

Outcome Measure	Time Frame
To explore the effect of N-acetyltransferase 2 (NAT2) genotype on the PK and metabolism of [14C] talampanel. To further assess the safety and tolerability of talampanel.	6-9 days

Collaborators and Investigators

• Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.
• Collaborators: Covance
• Investigators: Principal Investigator: Nicholas M Siebers, MD, Covance

Study record dates

Study Major Dates

• Study Start: May 1, 2009
• Primary Completion (Actual): September 1, 2009
• Study Completion (Actual): September 1, 2009

Study Registration Dates

• First Submitted: March 24, 2009
• First Submitted That Met QC Criteria: March 24, 2009
• First Posted (Estimate): March 25, 2009

Study Record Updates

• Last Update Posted (Estimate): September 16, 2009
• Last Update Submitted That Met QC Criteria: September 15, 2009
• Last Verified: September 1, 2009

More Information

Terms related to this study

• Keywords: Pharmacokinetics; Healthy Volunteers; Metabolites; Metabolism; Mass Balance; Talampanel
• Other Study ID Numbers: TAL-MB-100